ReviewCurrent gastroenterology reports2007
Refractory celiac disease.
Review in Current gastroenterology reports, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- ACG clinical guidelines: diagnosis and management of celiac disease.The American journal of gastroenterology · 2013Guideline
- Double-blind randomized controlled trial of rifaximin for persistent symptoms in patients with celiac disease.Digestive diseases and sciences · 2011Trial
- Neurological manifestation of coeliac disease with particular emphasis on gluten ataxia and immunological injury: a review article.Gastroenterology and hepatology from bed to bench · 2021Review
- Small intestinal bacterial overgrowth among patients with celiac disease unresponsive to a gluten free diet.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2020Article
- Refractory Celiac Disease Successfully Treated With Azathioprine.Gastroenterology research · 2017Article
- Creation of a model to predict survival in patients with refractory coeliac disease using a multinational registry.Alimentary pharmacology & therapeutics · 2016Article
- Despite sequence homologies to gluten, salivary proline-rich proteins do not elicit immune responses central to the pathogenesis of celiac disease.American journal of physiology. Gastrointestinal and liver physiology · 2015Article
- Salivary proline-rich proteins and gluten: Do structural similarities suggest a role in celiac disease?Proteomics. Clinical applications · 2015Article
- Advances in diagnosis and management of celiac disease.Gastroenterology · 2015Review
- The Prevalence of the Celiac Disease Among Urban Bedouin Population in Israel.Gastroenterology research · 2012Article
- A review of rifaximin and bacterial overgrowth in poorly responsive celiac disease.Therapeutic advances in gastroenterology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Celiac disease (CD) is a small intestinal inflammatory disorder characterized by an immune-mediated enteropathy triggered by the ingestion of wheat gluten or related rye and barley proteins in genetically predisposed individuals carrying the human leukocyte antigens (HLA)-DQ2 or -DQ8. Nonresponsive CD (NRCD) is a clinical diagnosis defined by the persistence of signs, symptoms, and/or laboratory abnormalities typical of CD despite adherence to a gluten-free diet for at least 6 months. One cause for NRCD is refractory CD (RCD), defined as the persistence of severe villous atrophy on small intestinal biopsy despite strict gluten withdrawal for at least 6 months with no evidence of other pathology. Although rare, RCD should be suspected in individuals with an established diagnosis of CD who fail to respond primarily or secondarily to a strict gluten-free diet, particularly if they manifest significant weight loss. A thorough evaluation must be performed to distinguish RCD from other causes of NRCD. RCD may be categorized into type I or type II. Type I RCD has a more favorable prognosis compared with type II and can often be managed with nutritional supplementation and possibly low level immunosuppressive therapy. Type II RCD carries a poor prognosis and is more likely to progress to life-threatening malnutrition or intestinal T-cell lymphoma. Immunosuppressive agents and, more recently, autologous stem cell transplant have been used to treat type II RCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.